Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience - PubMed (original) (raw)
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
Stefania Gelmini et al. Clin Chem Lab Med. 2007.
Abstract
Background: The enzyme tankyrase-1 (TNKS-1), a member of the growing family of poly(ADP-ribose) polymerases (PARPs), was identified as a component of the human telomeric complex. PARPs catalyze the formation of long chains of poly(ADP-ribose) onto protein acceptors using NAD(+) as a substrate. TNKS-1 interacts with the telomeric DNA-binding protein TTAGGG repeat-binding factor 1 (TRF1), which is a negative regulator of telomere length. TNKS-1 is a positive regulator of telomere elongation and its activity appears to be upregulated in some human cancers.
Methods: We evaluated for the first time TNKS-1 mRNA expression by real time RT-PCR in tumor tissue, paired normal mucosa and urine sediment in patients with transitional cell carcinoma (TCC) of the bladder. Samples were collected from 41 consecutive patients, 20 with non-muscle-invasive (pTa-pT1) and 21 with muscle-invasive (>/=pT2) bladder TCC. Results obtained in urine sediment were compared with those from 40 healthy subjects matched for age and sex.
Results: In pTa-pT1 tumor tissues, TNKS-1 mRNA levels were significantly higher than in >/=pT2 patients (p<0.0001). In urine sediment from TCC patients, independent of tumor stage, TNKS-1 mRNA levels were significantly higher than in healthy controls, with maximal levels in >/=pT2 patients. In particular, TNKS-1 mRNA levels in urine were elevated in 31/41 patients with a sensitivity of 81% in >/=pT2 tumors and 65% in pTa-pT1 TCC. Of patients with pTa-pT1 tumors, 11 had a recurrence within 18 months after initial transurethral resection. In these patients, urine levels of TNKS-1 mRNA were higher than in non-relapsing patients (p=0.038).
Conclusions: In this preliminary study, TNKS-1 mRNA in urine sediment from patients with bladder TCC correlated with tumor stage, and higher preoperative levels were associated with increased risk of early recurrence.
Similar articles
- Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
Eisemann T, Langelier MF, Pascal JM. Eisemann T, et al. J Biol Chem. 2019 Oct 4;294(40):14574-14590. doi: 10.1074/jbc.RA119.009200. Epub 2019 Aug 2. J Biol Chem. 2019. PMID: 31375564 Free PMC article. - Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
Malentacchi F, Vinci S, Della Melina A, Kuncova J, Villari D, Giannarini G, Nesi G, Selli C, Orlando C. Malentacchi F, et al. Urol Oncol. 2012 May-Jun;30(3):278-84. doi: 10.1016/j.urolonc.2010.05.009. Epub 2010 Sep 26. Urol Oncol. 2012. PMID: 20875751 - Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.
Matsutani N, Yokozaki H, Tahara E, Tahara H, Kuniyasu H, Haruma K, Chayama K, Yasui W, Tahara E. Matsutani N, et al. Int J Oncol. 2001 Sep;19(3):507-12. Int J Oncol. 2001. PMID: 11494028 - Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Müller M, Miller K, Schrader M. Christoph F, et al. Cancer Lett. 2007 Jan 8;245(1-2):121-6. doi: 10.1016/j.canlet.2005.12.038. Epub 2006 Feb 13. Cancer Lett. 2007. PMID: 16473461 - Seeding drug discovery: Telomeric tankyrase as a pharmacological target for the pathophysiology of high-altitude hypoxia.
Miglani M, Pasha Q, Gupta A, Priyadarshini A, Pati Pandey R, Vibhuti A. Miglani M, et al. Drug Discov Today. 2021 Nov;26(11):2774-2781. doi: 10.1016/j.drudis.2021.07.012. Epub 2021 Jul 22. Drug Discov Today. 2021. PMID: 34302973 Review.
Cited by
- Intracellular distribution of Tankyrases as detected by multicolor immunofluorescence techniques.
Bottone MG, Santin G, Soldani C, Veneroni P, Scovassi AI, Alpini C. Bottone MG, et al. Eur J Histochem. 2012 Jan 20;56(1):e4. doi: 10.4081/ejh.2012.e4. Eur J Histochem. 2012. PMID: 22472892 Free PMC article. - Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.
Andrew AS, Gui J, Hu T, Wyszynski A, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Ekstrom RM, Li Z, Zens MS, Borsuk M, Moore JH, Karagas MR. Andrew AS, et al. BJU Int. 2015 Feb;115(2):238-47. doi: 10.1111/bju.12641. Epub 2014 Mar 26. BJU Int. 2015. PMID: 24666523 Free PMC article. - Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Røe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K, Sundstrøm SH. Røe OD, et al. PLoS One. 2012;7(8):e40521. doi: 10.1371/journal.pone.0040521. Epub 2012 Aug 8. PLoS One. 2012. PMID: 22905093 Free PMC article. - Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients.
Shebzukhov YV, Lavrik IN, Karbach J, Khlgatian SV, Koroleva EP, Belousov PV, Kashkin KN, Knuth A, Jager E, Chi NW, Kuprash DV, Nedospasov SA. Shebzukhov YV, et al. Cancer Immunol Immunother. 2008 Jun;57(6):871-81. doi: 10.1007/s00262-007-0423-z. Epub 2007 Nov 20. Cancer Immunol Immunother. 2008. PMID: 18026951 Free PMC article. - Tankyrases/β-catenin Signaling Pathway as an Anti-proliferation and Anti-metastatic Target in Hepatocarcinoma Cell Lines.
Huang J, Qu Q, Guo Y, Xiang Y, Feng D. Huang J, et al. J Cancer. 2020 Jan 1;11(2):432-440. doi: 10.7150/jca.30976. eCollection 2020. J Cancer. 2020. PMID: 31897238 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials